Increased invasion and tumorigenicity capacity of CD44+/CD24- breast cancer MCF7 cells in vitro and in nude mice | springermedicine.com

Springer Medicine

Top

Cancer Cell International

Published in:

Open Access 01-12-2013 | Primary research

Increased invasion and tumorigenicity capacity of CD44⁺/CD24^- breast cancer MCF7 cells in vitro and in nude mice

Authors: Wenxing Yan, Yubing Chen, Yueliang Yao, Hongmei Zhang, Tiejun Wang

Published in: Cancer Cell International | Issue 1/2013

Login to get access

Abstract

Background

Identification of cancer stem cells (CSCs) and their behaviors will provide insightful information for the future control of human cancers. This study investigated CD44 and CD24 cell surface markers as breast cancer CSC markers in vitro and in vivo.

Methods

Flow cytometry with CD44 and CD24 markers was used to sort breast cancer MCF7 cells for scanning electron microscopy (SEM), tumor cell invasion assay, and nude mouse xenograft assay.

Results

Flow cytometry assay using CD44 and CD24 markers sorted MCF7 cells into four subsets, i.e., CD44⁺/CD24^-/low, CD44^-/CD24⁺, CD44⁺/CD24⁺, and CD44^-/CD24^-. The SEM data showed that there were many protrusions on the surface of CD44⁺/CD24^-/low cells. CD44⁺/CD24^-/low cells had many microvilli and pseudopodia. The CD44⁺/CD24^-/low cells had a higher migration and invasion abilities than that of the other three subsets of the cells. The in vivo tumor formation assay revealed that CD44⁺/CD24^- cells had the highest tumorigenic capacity compared to the other three subsets.

Conclusion

CD44 and CD24 could be useful markers for identification of breast CSCs because CD44⁺/CD24^-/low cells had unique surface ultrastructures and the highest tumorigenicity and invasive abilities.

Available only for authorised users

1.

Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF: Therapeutic implications of cancer stem cells. Curr Opin Genet Dev. 2004, 14: 43-47. 10.1016/j.gde.2003.11.007.CrossRefPubMed

2.

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003, 100: 3983-3988. 10.1073/pnas.0530291100.PubMedCentralCrossRefPubMed

3.

Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009, 69: 1302-1313. 10.1158/0008-5472.CAN-08-2741.PubMedCentralCrossRefPubMed

4.

Li F, Tiede B, Kang Y, Massagué J: Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 2007, 17: 3-14. 10.1038/sj.cr.7310118.CrossRefPubMed

5.

Velasco-Velázquez MA, Popov VM, Lisanti MP, Pestell RG: The role of breast cancer stem cells in metastasis and therapeutic implications. Am J Pathol. 2011, 179: 2-11. 10.1016/j.ajpath.2011.03.005.PubMedCentralCrossRefPubMed

6.

Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 2005, 5: 275-284. 10.1038/nrc1590.CrossRefPubMed

7.

Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63: 5821-5828.PubMed

8.

O'Brien CA, Pollett A, Gallinger S, Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007, 445: 106-110. 10.1038/nature05372.CrossRefPubMed

9.

Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008, 68: 4311-4320. 10.1158/0008-5472.CAN-08-0364.PubMedCentralCrossRefPubMed

10.

Tsuchiya S, Li F: Electron microscopic findings for diagnosis of breast lesions. Med Mol Morphol. 2005, 38: 216-224. 10.1007/s00795-005-0300-9.CrossRefPubMed

11.

Zhao YD, Huang Q, Zhang TY, Dong J, Wang AD, Ding F, Lan Q, Gu XS, Qin ZH: [Ultrastructural analysis of glioma stem cells-progenitors]. Zhonghua Zhong Liu Za Zhi. 2008, 30: 663-667.PubMed

12.

Paniz Mondolfi AE, Slova D, Fan W, Attiyeh FF, Afthinos J, Reidy J, Pang Y, Theise ND: Mixed adenoneuroendocrine carcinoma (MANEC) of the gallbladder: a possible stem cell tumor?. Pathol Int. 2011, 61: 608-614. 10.1111/j.1440-1827.2011.02709.x.CrossRefPubMed

13.

Pham PV, Phan NL, Nguyen NT, Truong NH, Duong TT, Le DV, Truong KD, Phan NK: Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med. 2011, 9: 209-10.1186/1479-5876-9-209.PubMedCentralCrossRefPubMed

14.

Zielske SP, Spalding AC, Wicha MS, Lawrence TS: Ablation of breast cancer stem cells with radiation. Transl Oncol. 2011, 4: 227-233.PubMedCentralCrossRefPubMed

15.

Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K: Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007, 11: 259-273. 10.1016/j.ccr.2007.01.013.CrossRefPubMed

16.

Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H: Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 2005, 11: 1154-1159.PubMed

17.

Wicha MS: Cancer stem cell heterogeneity in hereditary breast cancer. Breast Cancer Res. 2008, 10: 105-10.1186/bcr1990.PubMedCentralCrossRefPubMed

18.

Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K: Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res. 2010, 16: 876-887. 10.1158/1078-0432.CCR-09-1532.PubMedCentralCrossRefPubMed

19.

Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007, 1: 555-567. 10.1016/j.stem.2007.08.014.PubMedCentralCrossRefPubMed

20.

Smith GH, Chepko G: Mammary epithelial stem cells. Microsc Res Tech. 2001, 52: 190-203. 10.1002/1097-0029(20010115)52:2<190::AID-JEMT1005>3.0.CO;2-O.CrossRefPubMed

21.

Chepko G, Dickson RB: Ultrastructure of the putative stem cell niche in rat mammary epithelium. Tissue Cell. 2003, 35: 83-93. 10.1016/S0040-8166(02)00107-6.CrossRefPubMed

22.

Pierce GB, Nakane PK, Martinez-Hernandez A, Ward JM: Ultrastructural comparison of differentiation of stem cells of murine adenocarcinomas of colon and breast with their normal counterparts. J Natl Cancer Inst. 1977, 58: 1329-1345.PubMed

23.

Black PH: Shedding from the cell surface of normal and cancer cells. Adv Cancer Res. 1980, 32: 75-199.CrossRefPubMed

24.

Nicolson GL, Poste G: The cancer cell: dynamic aspects and modifications in cell-surface organization (first of two parts). N Engl J Med. 1976, 295: 197-203. 10.1056/NEJM197607222950405.CrossRefPubMed

25.

Spring FA, Dalchau R, Daniels GL, Mallinson G, Judson PA, Parsons SF, Fabre JW, Anstee DJ: The Ina and Inb blood group antigens are located on a glycoprotein of 80,000 MW (the CDw44 glycoprotein) whose expression is influenced by the In(Lu) gene. Immunology. 1988, 64: 37-43.PubMedCentralPubMed

26.

Sillanpää S, Anttila MA, Voutilainen K, Tammi RH, Tammi MI, Saarikoski SV, Kosma VM: CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clin Cancer Res. 2003, 9: 5318-5324.PubMed

27.

Li D, Zheng L, Jin L, Zhou Y, Li H, Fu J, Shi M, Du P, Wang L, Wu H, Chen GY, Zheng P, Liu Y, Wang FS, Wang S: CD24 polymorphisms affect risk and progression of chronic hepatitis B virus infection. Hepatology. 2009, 50: 735-742. 10.1002/hep.23047.CrossRefPubMed

28.

Nestl A, Von Stein OD, Zatloukal K, Thies WG, Herrlich P, Hofmann M, Sleeman JP: Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res. 2001, 61: 1569-1577.PubMed

29.

Aigner S, Ruppert M, Hubbe M, Sammar M, Sthoeger Z, Butcher EC, Vestweber D, Altevogt P: Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin. Int Immunol. 1995, 7: 1557-1565. 10.1093/intimm/7.10.1557.CrossRefPubMed

30.

Magee JA, Piskounova E, Morrison SJ: Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012, 21: 283-296. 10.1016/j.ccr.2012.03.003.PubMedCentralCrossRefPubMed

Title: Increased invasion and tumorigenicity capacity of CD44+/CD24- breast cancer MCF7 cells in vitro and in nude mice
Authors: Wenxing Yan
Yubing Chen
Yueliang Yao
Hongmei Zhang
Tiejun Wang
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Cancer Cell International / Issue 1/2013
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/1475-2867-13-62

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties